“The OxC-beta pet product is a breakthrough because of its proven results to optimize overall health. It’s like the discovery of a new class of vitamins—it’s unique, affordable and easy, prompting an increase in sales worldwide.”
– Jolyon Burton
President and Head of Investment Banking, Bloom Burton & Co.
News & Media
Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta™ Product Published in Peer-Reviewed Journal
Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective Product’s value
Avivagen Inc. Announces Securites for Service Agreements with CEO and CSO
Ottawa, ON / Business Wire/ December 22nd 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation
Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares
Ottawa, ON / Business Wire/ October 31, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation
Avivagen has developed and is commercializing naturally-derived flavoring agents that help optimize feed intake which promotes health in livestock.
Avivagen offers its commercial partners scientifically backed, evidence-based products which are in high demand from multiple channels including veterinarians, farmers and producers, pet owners and retailers.
Avivagen maintains the highest manufacturing standards and is a proud member of the NASC, a self-regulating body, which protects and enhances the integrity of the animal health product industry.
Avivagen is actively collaborating with companies in Canada, the United States, the Philippines, Korea, Vietnam, and Thailand, and we are seeking more relationships internationally.
